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Abstract 
Background 
Peripheral arterial disease (PAD) results in reduced health-related quality of life and significant 
functional impairment. Patient-reported outcome measures (PROMs) are important when considering 
the impact of treatments and management strategies in patients with PAD.  A variety of studies have 
reported the use of different PROMs in patients with PAD.  However, PROMs should provide valid 
and reliable findings to help in healthcare decision-making. The aim of this proposed systematic 
review is to comprehensively evaluate the psychometric properties of PROMs developed and/ or 
validated in patients with PAD. 
 
Methods 
Computerised searches will be conducted in major electronic databases and PROM-specific 
databases. Searches will be supplemented by checking reference lists of identified relevant studies. 
Studies reporting and/or comparing the measurement properties of PROMs in English-speaking 
patients with a diagnosis of PAD will be considered for inclusion. Study selection, data extraction and 
quality assessment will be performed independently by at least 2 reviewers. Methodological quality of 
included studies will be assessed using the COSMIN checklist while criteria based on published 
recommendations will be used to appraise reported psychometric properties.  Findings will be 
presented as narrative and tabular summaries. 
 
Discussion 
This systematic review will provide an overview of available psychometric properties of PROMs to 
help identify a suitable measure for capturing health-related quality of life and functional or health 
status in patients with PAD. 
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Background 
Peripheral artery disease (PAD) of the lower extremities is caused by atherosclerosis in the arteries of 
the legs and results in reduction in blood circulation to affected tissues and muscles.1;2;3 Available 
literature suggests that clinical diagnosis and classification of PAD is often based on varying criteria. 
A few of these include the International Society for Cardiovascular Surgery (ISCVS) recommended 
standards4-6, the Edinburgh Claudication Questionnaire7 and several cut-offs of ankle brachial 
pressure indices at rest or following exercise7-10. Consequently, the prevalence of PAD typically 
differs depending on criteria used for the identification of patients. In general, it is estimated that a 
third of individuals aged 70 years and over are affected by PAD2.  
 
While most patients tend to be asymptomatic for many months or years, symptomatic patients 
experience significant functional limitations and reduced health related quality of life (HRQoL)11-15. 
Symptoms and signs of PAD are closely related to the severity of impaired blood supply in the 
affected vasculature. Pain in the calf muscles triggered by walking and relieved by resting is one of 
the commonest and earliest symptoms of PAD. This clinical presentation is known as intermittent 
claudication. Other manifestations of PAD include pain in the legs at rest, ulceration and gangrene 
which may subsequently result in amputation. Management strategies for patients with PAD aim to 
improve symptoms, delay progression, prevent tissue loss and modify risk factors1;16  
 
Patient-reported outcome measures (PROMs) are considered to be useful when assessing the health of 
patients as well as the performance of healthcare systems. The National Health Service (NHS) in 
England introduced the PROMs programme in April 2009. The programme encourages all patients 
undergoing varicose vein surgery, groin surgery and hip or knee replacement to provide PROMs data 
before and after treatment. PROMs may be obtained through self-administered or interviewer-
administered questionnaires. Presently, PROMs are not collected from patients with PAD4. 
Appropriate outcome measures are needed for capturing the impact of treatments of patients and also 
for informing decisions about treatments.  To provide information useful for health-care decision-
making, a suitable PROM must be valid, reliable, responsive and acceptable to the patient and 
attending healthcare providers. The aim of this review is to identify, critically appraise and synthesise 
evidence relating to the psychometric performance of PROMs in patients with PAD. 
 
Review questions to be answered by this systematic review are as follows: 
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● Which PROMS have been validated (i.e. assessed using psychometric criteria) in patients 
with PAD? 
● To what extent do the reported psychometric properties of identified PROMs meet 
recommended criteria?  
● What is the methodological quality of the relevant studies?  
● What is the quality of reporting of relevant studies? 
 
Methods  
 
The protocol was developed and agreed following extensive consultation within a multi-disciplinary 
research team comprising methodological and clinical experts.   
 
Literature searching 
Computerised literature searching of major bibliographic databases using a two-staged approach will 
be undertaken in the following databases from their dates of inception: MEDLINE and MEDLINE in 
Process; EMBASE; Cochrane Library; CINAHL; PsycINFO; Web of Science. 
 
Stage 1 searching will aim to identify studies reporting PROMs in patients with PAD. Three sets of 
terms, including Medical Subject Heading (MESH) terms and free text terms, relating to (1) PAD; (2) 
known generic PROMs and (3) known condition-specific PROMs will be included in the search 
strategy.  Stage 2 searching will be undertaken to identify studies reporting the development and/or 
validation of identified PROMs. The search strategy will consist of terms for (1) the population of 
interest (as used in Stage 1 searching) and (2) known generic and condition-specific PROMs (as used 
in Stage 1 searching together with additional terms identified from sifting records of the first search) 
and (3) a methodological search filter for locating studies reporting measurement properties.  
 
The search strategy will be developed by an experienced information specialist in consultation with 
methodological and topic experts and will be adapted for searching within different databases, when 
necessary. Searches will be undertaken by an information specialist.  All retrieved records will be 
imported and managed within a reference management database. 
 
Supplementary searches will include searching the PROQOLID and PROMS Bibliography (Oxford 
University) databases; checking reference lists of relevant studies and reviews; and searching grey 
literature using the Google Scholar search engine. 
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Study eligibility 
Study eligibility will be based on agreed criteria as summarised in Table 1. 
 
Table 1: Criteria for considering eligibility of studies 
  INCLUSION CRITERIA EXCLUSION CRITERIA 
Population  A defined population of English-
speaking participants with a diagnosis of 
peripheral arterial disease of the lower 
limbs, also described as peripheral 
vascular disease; peripheral obliterative 
arteriopathy; peripheral arterial 
occlusive disease  
 
OR 
 
Patients with rest pain; claudication; 
vascular spasms; ischaemic ulceration; 
amputation; necrosis or gangrene of the 
limb due to PAD  
Undefined population of PAD patients
 
 
 
 
 
 
OR 
 
Patients with rest pain; claudication; 
vascular spasms; ischaemic ulceration; 
amputation; necrosis or gangrene of the 
limb due to any cause other than PAD 
Interventions  No intervention or any intervention 
indicated for PAD 
 
 
Outcomes  PROMs1 covering  any of the following: 
generic or  preference-based measures 
e.g. EQ-5D, SF-6D, SF-36; directly 
elicited preference-based measures e.g. 
time-trade-off (TTO), standard gamble 
(SG) utility values; condition-specific 
outcome measures; functional outcome 
measures 
 
English version of PROMs 
Outcome measures of patient 
satisfaction or experience of treatment 
or  outcome measures obtained from 
proxies, carers or health providers 
 
 
 
 
 
Non-English versions of PROMs 
 
Study type  Published validation studies, other than 
linguistic validation of English versions 
of relevant PROMs 
 
 
 
 
 
Publication in English 
Unpublished studies 
 
Studies of linguistic validation of 
PROMs 
 
Review articles, letters, commentaries, 
abstracts 
 
Non-English publications 
 
 
                                                            
1 See list of relevant PROMS in Appendix 1 
 5 
 
Types of participants 
A study will be eligible for inclusion if it reports on a well-defined English-speaking population (age, 
> 18 years) with an objective clinical diagnosis of PAD.  Studies in countries where English is not the 
official language will be excluded, unless the study reports PROMs obtained from an English 
speaking study sub-group. Studies evaluating patients with self-reported PAD will also be excluded. 
Studies with PROM data for a heterogeneous study population including patients with PAD will be 
excluded if the sub-group of patients with PAD is less than 50% or if there is no PROM data for the 
relevant study population of patients with PAD. 
 
Types of interventions 
It was anticipated that the study design of relevant studies will be wide-ranging. Studies will be 
considered for inclusion whether or not patients received any intervention for PAD.  
 
Types of outcome measures 
Primary outcomes 
● Reported PROMs will include generic or condition-specific instruments capturing health-
related quality of life, health status and functional well-being 
● Reported psychometric properties of identified PROMs  will include:  
(1) Validity (that is, the degree to which the instrument measures what it is supposed to 
measure);  
(2) Reliability (that is, the degree to which measures are reproducible and consistent over time 
in patients with a stable condition);  
(3)  Responsiveness (that is, the degree to which the instrument detects meaningful change 
over time) and  
(4) Acceptability (that is, the degree to which the instrument is acceptable to the patient). 
 
Secondary outcomes 
● Reported domains of relevant PROMS  
 
Types of studies 
Primary studies published in English reporting the validation of relevant PROMs in the population of 
interest will be eligible for inclusion. Validation implies the assessment of one or more psychometric 
or measurement properties of a PROM. Studies reporting on non-English translations of relevant 
PROM instruments or PROMs elicited from non-English speakers will be excluded. This is an 
 6 
 
acceptable approach to overcome the uncertainty due to language validation and cross-cultural 
adaptation of PROMs17.   
 
Publication types that will be excluded include conference abstracts, editorials, commentaries and 
letters. 
 
Study selection 
Study selection will be undertaken independently by at least two reviewers using pre-specified criteria 
as presented in Table 1. Disagreements will be resolved by discussion and referred to a third reviewer, 
when needed. 
 
Data extraction 
Data will be extracted using a piloted standardised electronic form by one reviewer to construct 
evidence tables. Abstracted data will include the study’s aim(s), characteristics of study population 
including diagnostic criteria, identified PROMS as well as their contents/domains, reported 
psychometric properties, timing and method(s) of administration.  Discrepancies will be checked by a 
second reviewer and discussed between researchers. Where consensus cannot be achieved, a third 
reviewer will be consulted. 
 
Methodological quality assessment 
For each identified PROM, methodological quality of included studies and reported psychometric 
properties will be evaluated by one researcher. Ambiguities will be resolved by discussion with a 
second researcher.   It is anticipated that a wide range of study designs will be eligible for inclusion; 
therefore quality assessment will focus on the following: 
● Assessment of methodological quality of included studies based on criteria recommended in 
the COnsensus-based Standards for the selection of health status Measurement INstruments 
(COSMIN) checklist19 will be undertaken. Scoring will be limited to reported psychometric 
properties in each study, based on a 4-point rating scale (excellent, good, fair or poor). 
Subsequently, a “worst score counts method”18 will be used to provide an overall domain 
score. 
 
● Assessment of psychometric properties of validated PROMs based on published standardised 
criteria from a number of sources will be used to examine the psychometric performance of 
validated PROMS. Appraisal criteria to be considered are presented in Table 2. 
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Table 2: Criteria for assessing the psychometric properties of PROMs 
DOMAIN DESCRIPTIVE CRITERIA 
Test re-test reliability 
 
The intra-class correlation/ weighted kappa score should be ≥0.70 for 
group comparisons and ≥ 0.90 if scores are going to be used for 
decisions about an individual based on their score19.  
  
The mean difference (paired t-test or Wilcoxon signed-rank test) 
between time point 1 (T1) and time point 2 (T2) and the 95% CI should 
also be reported. 
 
Internal consistency 
 
A Cronbach’s alpha score of ≥0.70 is considered good and it should 
not exceed ≥0.92 for group comparisons as this is taken to indicate that 
items in the scale could be redundant.  Item total correlations should be 
≥0.2020.  
 
Content validity 
 
This is assessed qualitatively during the development of an instrument. 
To achieve good content validity, there must be evidence that the 
instrument has been developed by consulting patients, experts as well 
as undertaking a literature review.  
 
Patients should be involved in the development stage and item 
generation. The opinion of patient representatives should be sought on 
the constructed scale19-21. 
 
Construct validity A correlation co-efficient of ≥0.60 is taken as strong evidence of 
construct validity. Authors should make specific directional 
hypotheses and estimate the strength of correlation before testing19;20;22. 
 
Criterion validity 
 
A good argument should be made as to why an instrument is a gold 
standard and correlation with the gold standard should be ≥ 0.7022 .  
 
Responsiveness 
 
There are a number of methods to measure this including t-tests, effect 
size, standardised response means or responsiveness statistics Guyatts’ 
responsiveness index. There should be statistically significant changes 
in score of an expected magnitude23.  
Floor-ceiling effects  A floor or celling effect is considered if 15% of respondents are 
achieving the lowest or the highest score on the instrument22. 
Acceptability  
 
Acceptability was measured by the completeness of the data supplied. 
80% or more of the data should be complete21.  
 
Domain mapping and data synthesis 
Due to the expected heterogeneity of eligible studies, a meta-analysis is unlikely or may be 
inappropriate to undertake. Findings of this review will be presented in narrative and tabular 
summaries to provide an overview of characteristics of included studies as well as the contents, 
scoring and psychometric performance of identified PROMs. The methods for summarising 
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information on the psychometric criteria including methodological quality will be informed by the 
Oxford system and the COSMIN checklist23;24 In general, the combined rating scales will be as 
follows: 
[0] for not reported (no evaluation completed), 
[-] for evidence not in favour,  
[+/-] for conflicting evidence and  
[+] for evidence in favour 
 
Analysis of subgroups or subsets 
None planned 
 
Dissemination plans 
The findings of the review will be published as a report to the funders; in peer-reviewed journals and 
as conference proceedings. 
 
Discussion 
This protocol of a planned systematic review of PROMs validated in patients with PAD clearly 
outlines methods for identifying, appraising and collating available evidence. The findings of the 
review will inform re-configuration of vascular services in the United Kingdom. In April 2009, the 
National Health Service (NHS) encouraged that PROM data should be obtained from patients 
undergoing knee replacement,  hip replacement,  groin hernia and varicose vein surgery25. Currently, 
there is no routine collection of PROMs from patients with PAD. 
 
Strengths and limitations of the review 
Potential strengths of the planned review include the comprehensive and iterative literature searching 
to identify studies as well as the involvement of a multi-disciplinary team of clinical and 
methodological experts. To ensure robustness of the review, study selection, data extraction and 
quality assessment will be undertaken independently by at least two reviewers. Additionally, the 
scope of the review is broader compared to an earlier systematic review which focussed on patients 
with intermittent claudication.  
 
A decision to include studies examining English version of PROMs administered to predominantly 
English-speakers could be considered as a weakness of the review. On the other hand, this approach is 
appropriate for identifying and proposing a single PROM for use in the United Kingdom (UK). This is 
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of significant importance considering conflicting or unclear evidence with regard to linguistic 
validation and cross-cultural validation of some existing PROMS17.  
 
Relevance of the review 
The utility of validation studies of psychometric properties of PROMs substantial rely on clear and 
detailed reporting of primary studies. By examining the methods and timing of PROM administration 
as well as methodological quality of identified PROMs, the planned review will overcome one of the 
hurdles in assess the generalisability of findings from validation studies20. 
 
In general, it is anticipated that the findings of this review will be supplemented by qualitative 
evidence to inform the recommendation and subsequent selection of a single PROM which is 
appropriate for assessing the impact of treatment in patients with PAD within the NHS. 
 
Funding  
Source of funding for research: This research is funded through the National Institute for Health 
Research Programme Grant (Project ID: RP-PG-1210-12009).
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Appendix 1 
List of patient-reported outcome measures considered as potentially 
relevant in patients with peripheral arterial disease 
 
 
1. Activities‐specific	Balance	Confidence	(ABC)	Scale	 
2. AMC	linear	disability	score	(ALDS)	 
3. Amputee	Body	Image	Scale	(ABIS) 
4. Assessment	of	Quality	of	Life	(AQoL‐4D		or	AQoL‐8D)	
questionnaire
5. Australian	Vascular	Quality	of	Life	Index	(AUSVIQUOL) 
6. Baltimore	Activity	Scale	for	Intermittent	Claudication	
(BASIC)	
7. Beck	Anxiety	Inventory 
8. Beck	Depression	Inventory 
9. Berg	Balance	Scale 
10. Centre	for	Disease	Control	and	Prevention	Health‐Related	
Quality	of	Life	4	question	set 
11. Charing	Cross	Claudication	Questionnaire	(CCCQ)	
12. Claudication	Scale	(CLAU‐S)	questionnaire 
13. Community‐based	walking	ability 
14. Comprehensive	High	Level	Activity	Mobility	Predictor	
(CHAMP)
15. Cumulative	Illness	Rating	Scale	(CIRS)
16. Discomfort‐Engagement	in	everyday	activities	involving	
revealing	the	body	(Discomfort‐EEARB)	scale
17. Disease‐specific	Questionnaire	for	Quality	of	Life	in	Patients	
with	Peripheral	Arterial	Occlusive	Disease	in	the	Stage	of	
Critical	Ischemia	(FLeQKI)
18. Engagement	in	everyday	activities	involving	revealing	the	
body	(EEARB)	scale
19. EQ‐5D;	EQ‐5D	5L 
20. Estimating	Ambulation	Capacity	by	History‐Questionnaire	
(EACH‐Q)
21. Frenchay	Activities	Index 
22. Functional	Independence	Measure	(FIM)
23. Functional	Limitations	Profile 
24. Geriatric	Depression	Scale	(GDS) 
25. Global	Mood	Scale 
26. Health	Utilities	Index‐Mark	III	(HUI‐III)
27. Hospital	Anxiety	and	Depression	Scale	(HADS) 
28. Houghton	scale	
29. Intermittent	Claudication	Questionnaire	(ICQ) 
30. King's	College	Hospital's	Vascular	Quality	of	Life	
Questionnaire	(Vas‐QoL)
31. London	School	of	Hygiene	IC	Questionnaire	 
32. McGill	Pain	Questionnaire 
33. McMaster	Health	Index	Questionnaire	(MHIQ) 
34. Mental	component	scale	(MCS) 
35. Modified	WHO‐Edinburgh	Claudication	Questionnaire 
36. MOS‐SS	questionnaire	for	social	support 
37. Nottingham	Health	Profile	(NHP) 
38. Nottingham	Health	Profile	index	of	Depression	(NHPD) 
39. Orthotics	and	Prosthetics	Users'	Survey	(OPUS) 
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40. PAD	Quality	of	life	questionnaire	(PADQOL) 
41. Pain	Interference	Scale	of	the	Brief	Pain	Inventory	 
42. PAOD	Physical	Activity	Recall 
43. Patient	Generated	Index 
44. Patient	Health	Questionnaire 
45. PAVK‐86 
46. Peripheral	Artery	Questionnaire	(PAQ) 
47. Positive	Attitude	Toward	Physical	Activities/Exertion	
Questionnaire
48. Profile	of	Mood	States	(POMS) 
49. Prosthetic	Evaluation	Questionnaire	(PEQ) 
50. Prosthetics	Evaluation	Questionnaire	(PEQ) 
51. Quality	of	Well	Being	scale 
52. Rand‐36	DLV 
53. Rand‐36	Physical	Functioning	subscale 
54. Roland‐Morris	Disability	Questionnaire. 
55. Rose	questionnaire 
56. Rosser	index/Scale 
57. San	Diego	Claudication	Questionnaire 
58. Satisfaction	with	Prosthesis	Questionnaire	(SAT‐PRO) 
59. Self‐reported	Life	Satisfaction	(LS)	score 
60. SF‐8;	SF‐6;	SF‐12;	SF‐20;	SF‐36 
61. Short‐Form	Health	Survey	questionnaire	adapted	for	the	
veteran	population	(SF‐36V) 
62. Sickness	Impact	Profile	‐	Intermittent	Claudication	(SIP(IC)) 
63. Sickness	Impact	Profile	(SIP) 
64. Standard	gamble 
65. Time‐trade	off	(TTO) 
66. Vascular	Quality	of	life	(VascuQol) 
67. Verbal	rating	scale 
68. Walking	impairment	questionnaire 
69. WHO	Intermittent	claudication	questionnaire 
70. WHOQOL‐100	 
71. World	Health	Organization	Quality	of	Life‐BREF	(WHOQOL‐
BREF)
72. Zung‐SDS	(depression	symptoms) 
73. 15D	Health‐related	QoL	instrument 
74. 6‐item	Brief	Social	Support	Questionnaire 
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